One option for the management of low-grade (Gleason score of ≤6) and low-stage (T1c or T2a) prostate cancer with PSA levels of ≤10 ng/mL is to delay or forego more aggressive treatment unless evidence of an increased risk of disease progression exists. This evidence concerns the gene KLK3 and Familial prostate cancer.